Agnostic anti-mullerian hormone receptor binding peptides
Disclosed are compositions and methods including Anti-Müllerian Hormone (AMH) receptor binding peptides. The AMH receptor binding peptides can be used, for example, to modify the activity of the AMH receptor. For example, the AMH receptor binding peptides can activate the AMH receptor, such as the AMH receptor 2, thereby mimicking the function of AMH. In other examples, the AMH receptor binding peptides function as AMH receptor antagonists, thereby interfering with the function of endogenous AMH. By modifying the activity of the AMH receptor, the peptides have multiple applications, including for example modification of treatment of precocious puberty in females, delay of natural menopause, preservation of ovarian follicular reserve, contraception, fertility preservation after ovarian cortex transplant, treatment of endometriosis, treatment of cancer and/or cancer prevention, and treatment of polycystic ovary syndrome (PCOS).
1 . An anti-Mullerian hormone receptor 2 (AMH-R 2 ) binding peptide comprising any one of the amino acid sequences set forth as SEQ ID NOS: 1-20, wherein each of the amino acid sequences set forth as SEQ ID NOS: 1-20 optionally comprises no more than two amino acid substitutions.
2 . The AMH-R 2 binding peptide of claim 1 , wherein the AMH-R 2 binding peptide is an AMH-R 2 agonist.
3 . The AMH-R 2 binding peptide of claim 1 , wherein the amino acid sequence set forth as any one of SEQ ID NOS: 1-20 further comprises at least one D-form amino acid.
4 . The AMH-R 2 binding peptide of claim 1 , wherein the C-terminus amino acid residue is selected from the group consisting of a glycine, serine, leucine, alanine, and valine residue.
5 . The AMH-R 2 binding peptide of claim 1 , wherein the AMH-R 2 binding peptide comprises at least one modified amino acid.
6 . The AMH-R 2 binding peptide of claim 1 , wherein the AMH-R 2 binding peptide comprises the sequence set forth as any one of SEQ ID NOS: 1-5.
7 . The AMH-R 2 binding peptide of claim 6 , wherein the AMH-R 2 binding peptide optionally comprises no more than one amino acid substitution.
8 . The AMH-R 2 binding peptide of claim 6 , wherein the AMH-R 2 binding peptide comprises the sequence set forth as any one of SEQ ID NOS: 1, 3, or 5.
9 . The AMH-R 2 binding peptide of claim 8 , wherein the AMH-R 2 binding peptide optionally comprises no more than one amino acid substitution.
10 . The AMH-R 2 binding peptide of claim 6 , wherein the AMH-R 2 binding peptide comprises the sequence set forth as SEQ ID NO: 1 or SEQ ID NO: 5.
11 . The AMH-R 2 binding peptide of claim 10 , wherein the AMH-R 2 binding peptide optionally comprises no more than one amino acid substitution.
12 . The AMH-R 2 binding peptide of claim 2 , wherein the AMH-R 2 binding peptide comprises the amino acid sequence set forth as any one of SEQ ID NOS: 1, 3, or 5.
13 . A composition for use in stimulating an anti-Mullerian hormone receptor 2 (AMH-R 2 ), the composition comprising an AMH-R 2 binding peptide, the AMH-R 2 binding peptide comprising any one of the amino acid sequences set forth as SEQ ID NOS: 1-20, wherein each of the amino acid sequences set forth as SEQ ID NOS: 1-20 optionally comprises no more than two amino acid substitutions.
14 . The composition of claim 13 , further comprising a pharmaceutically acceptable carrier.
15 . The composition of claim 14 , wherein the pharmaceutically acceptable carrier comprises a buffered aqueous solution.
16 . The composition of claim 14 , wherein the composition is formulated for parenteral administration.
17 . The composition of claim 14 , wherein the composition is formulated for subcutaneous administration.
18 . The composition of claim 14 , wherein the composition is formulated for intravenous administration.
19 . The composition of claim 14 , wherein the composition is formulated for topical administration.
20 . The composition of claim 13 , wherein the AMH-R 2 binding peptide comprises the amino acid sequence set forth as any one of SEQ ID NOS: 1, 3, or 5.